Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 11322

1.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 3. doi: 10.1093/annonc/mdy217. [Epub ahead of print]

PMID:
30113631
2.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2018 Aug 13. doi: 10.1093/annonc/mdy255. [Epub ahead of print] No abstract available.

PMID:
30107447
3.

Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma.

Sathasivam HP, Santambrogio A, Andoniadou CL, Robinson M, Thavaraj S.

Ann Oncol. 2018 Aug 8. doi: 10.1093/annonc/mdy313. [Epub ahead of print] No abstract available.

PMID:
30101315
4.

Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical Advances.

Hemming ML, Heinrich MC, Bauer S, George S.

Ann Oncol. 2018 Aug 8. doi: 10.1093/annonc/mdy309. [Epub ahead of print]

PMID:
30101284
5.

Heterogeneity of EGFR-mutant clones and PD-L1 highly-expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.

Ann Oncol. 2018 Aug 7. doi: 10.1093/annonc/mdy312. [Epub ahead of print] No abstract available.

PMID:
30099497
6.

Overall Survival and Risk of Second Malignancies with Cancer Chemotherapy and G-CSF Support.

Lyman GH, Yau L, Nakov R, Krendyukov A.

Ann Oncol. 2018 Aug 7. doi: 10.1093/annonc/mdy311. [Epub ahead of print]

PMID:
30099478
7.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M.

Ann Oncol. 2018 Aug 2. doi: 10.1093/annonc/mdy253. [Epub ahead of print]

PMID:
30084934
8.

Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication.

Liang F, Zhu J, Mo M, Zhou CM, Jia HX, Xie L, Zheng Y, Zhang S.

Ann Oncol. 2018 Aug 2. doi: 10.1093/annonc/mdy305. [Epub ahead of print]

PMID:
30084933
9.

Targeting gamma secretase: has progress moved up a notch?

Dumbrava EI, Mills GB, Yap TA.

Ann Oncol. 2018 Aug 2. doi: 10.1093/annonc/mdy307. [Epub ahead of print] No abstract available.

PMID:
30084907
10.

Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.

Mauri G, Bencardino K, Sartore-Bianchi A, Siena S.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy306. [Epub ahead of print] No abstract available.

PMID:
30060112
11.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy261. [Epub ahead of print] No abstract available.

PMID:
30060089
12.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study.

de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy256. [Epub ahead of print]

PMID:
30060083
13.

First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy244. [Epub ahead of print]

PMID:
30060061
14.

Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer.

Grothey A, Shah M, Yoshino T, Van Cutsem E, Taieb J, Xu R, Tebbutt NC, Falcone A, Cervantes A; other CanStem303 Investigators, Borodyansky L, Li CJ.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx783. No abstract available.

PMID:
30052795
15.

Corrigendum.

[No authors listed]

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx549. No abstract available.

PMID:
30052794
16.

LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial.

Bouattour M, Assenat E, Guiu B, Ilonca Alina D, Pageaux GP, Sibert A, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Pereira H, Castera L, Chatellier G, Vilgrain V; SARAH Trial Group.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302. No abstract available.

PMID:
30052793
17.

LBA-010Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

Sinicrope Frank A, Shi Q, Hermitte F, Heying E, Benson Al B, Gill S, Goldberg Richard M, Kahlenberg M, Nair S, Shields A, Sargent D, Galon J, Alberts Steven R.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.009. No abstract available.

PMID:
30052792
18.

LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer.

Catenacci Daniel V, Wainberg Z, Fuchs Charles S, Garrido M, Bang YJ, Muro K, Savage M, Wang J, Koshiji M, Dalal Rita P, Kang YK.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.008. No abstract available.

PMID:
30052791
19.

LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO).

Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley Kim B, Schmiegel Wolff H, Folprecht G, Probst S, Prasnikar N, Thuss-Patience Peter C, Trojan J, Goetze TO, Meiler J, Schuler Martin H, Jäger E, Hofheinz RD.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.007. No abstract available.

PMID:
30052790
20.

LBA-007FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis.

Schmoll HJ, Garlipp B, Junghanß C, Leithäuser M, Vogel A, Schaefers M, Kaiser U, Hoeffkes HG, Florschütz A, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Steighardt J, Cygon F, Meinert F, Stein A.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.006. No abstract available.

PMID:
30052789

Supplemental Content

Loading ...
Support Center